A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696

Trial Profile

A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 12 Mar 2018 This study is completed in Portugal (End date: 2017-12-27).
    • 06 Mar 2018 This trial has been completed in Poland (End date: 2017-12-27).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top